natgillin/translations-raw huggingface dataset:
A prospective Phase III, international, randomised (1:1), open-label clinical study (MMY-3002 VISTA) of 682 patients was conducted to determine whether VELCADE (1.3 mg/m2 injected intravenously) in combination with melphalan (9 mg/m2) and prednisone (60 mg/m2) resulted in improvement in time to progression (TTP) when compared to melphalan (9 mg/m2) and prednisone (60 mg/m2) in patients with previously untreated multiple myeloma.
Za ugotovitev ali uporaba zdravila VELCADE (1,3 mg/m2 intravensko) v kombinaciji z melfalanom (9 mg/m2) in prednizonom (60 mg/m2) prispeva k podaljšanju časa do napredovanja bolezni (Time To Progression-TTP) v primerjavi z zdravljenjem samo z melfalanom (9 mg/m2) in prednizonom (60 mg/m2), pri bolnikih s predhodno nezdravljenim diseminiranim plazmocitomom, so izvedli prospektivno, mednarodno, randomizirano (1:1) odprto klinično študijo faze III (MMY-3002 VISTA) pri 682 bolnikih.
A prospective, open-label, non-randomized, uncontrolled study (RE-VERSE AD) is currently ongoing to investigate the treatment of adult patients who presented with dabigatran-related life-threatening or uncontrolled bleeding (Group A) or who required emergency surgery or urgent procedures (Group B).
Trenutno poteka prospektivna, odprta, nerandomizirana, nenadzorovana študija (RE-VERSE AD) za proučitev zdravljenja odraslih bolnikov, ki imajo življenjsko nevarno ali nenadzorovano krvavitev, povezano z dabigatranom (skupina A), ali potrebujejo nujno operacijo ali nujni poseg (skupina B).
A protective immune response may not be elicited in all vaccinees (see section 5.1).
Zaščitni imunski odziv morda ne bo doseţen pri vseh cepljenih osebah (glejte poglavje 5.1).
A protective immune response may not be elicited in all vaccines.
Zaščitni imunski odziv morda ne bo dosežen pri vseh cepljenih osebah.
A protective liner covers the sticky side of the patch.
Lepljivo stran obliža pokriva zaščitna plast.
A protective response may not be elicited in all vaccinees (see section 5.1).
Zaščitni odziv morda ne bo sprožen pri vseh cepljenih osebah (glejte poglavje 5.1).
A protective response may not be induced in all vaccinees (see section 5.1).
Zaščitni odziv morda ne bo dosežen pri vseh cepljenih osebah (glejte poglavje 5.1).
A protein C activity of 100 % should be achieved initially and the activity should be maintained above 25 % for the duration of the treatment.
Na začetku morate doseči 100 % aktivnost proteina C in jo potem ohranjati nad 25 % ves čas zdravljenja.
a proton pump inhibitor (e.g, omeprazole) for upset stomach
ali če jemljete kakšen zaviralec protonske črpalke (npr. omeprazol) zaradi težav z želodcem,
a proton pump inhibitor (e.g, omeprazole) for upset stomach
zaviralec protonske črpalke (npr. omeprazol) zaradi težav z želodcem,
a proton pump inhibitor (e.g, omeprazole) for upset stomach,
zaviralec protonske črpalke (npr. omeprazol) zaradi težav z želodcem,
A pump malfunction or obstruction of the infusion set can result in a rapid rise in glucose levels.
Nepravilno delovanje crpalke ali zamašitev infuzijskega kompleta lahko povzroci hitro zvišanje koncentracije glukoze v krvi.
A puncture resistant container for disposal of used pens
lepljivi povoj/obliž, neprebojni vsebnik za odlaganje uporabljenih peresnikov.
A puncture resistant container for disposal of used syringes
lepljivi povoj/obliž, neprebojni vsebnik za odlaganje uporabljenih brizg.
a puncture-proof container for safe disposal of the used syringe.
vsebnik, odporen proti vbodom, za varno odlaganje uporabljene brizge.
A puncture-proof container for safe disposal of the used syringes and needles
alkoholne blazinice, neprebodni vsebnik za varno odstranjevanje uporabljenih injekcijskih brizg in igel.
A QTc study performed with naloxegol in healthy volunteers did not indicate any prolongation of the QT interval.
Študija intervala QTc, ki so jo izvedli z naloksegolom pri zdravih prostovoljcih, ni pokazala podaljšanja QT intervala.
A qualified and experienced doctor or physician in the treatment of cancer will inject DepoCyte in the spinal fluid or lumber sac.
Usposobljen in izkušen zdravnik za zdravljenje raka vam bo zdravilo DepoCyte injiciral v hrbtenjačno tekočino ali lumbalno vrečko.
A questionnaire to gather detailed ADR report documentation.
Vprašalnik, s katerim bo zbrana podrobna dokumentacija za neželeni učinek.
a RA study I at 24 weeks, RA study II at 26 weeks , and RA study III at 24 and 52 weeks b 40 mg Humira administered every other week c MTX = methotrexate
a Študija revmatoidnega artritisa I po 24 tednih, študija revmatoidnega artritisa II po 26 tednih in študija revmatoidnega artritisa III po 24 in 52 tednih b 40 mg zdravila Humira vsak drugi teden c MTX = metotreksat
a RA study I at 24 weeks, RA study II at 26 weeks , and RA study III at 24 and 52 weeks b 40 mg Humira administered every other week c MTX = methotrexate
a Študija revmatoidnega artritisa I po 24 tednih, študija revmatoidnega artritisa II po 26 tednih in študija revmatoidnega artritisa III po 24 in 52 tednih b 40 mg zdravilo Humira vsak drugi teden c MTX = metotreksat
A randomised and controlled clinical trial (EGF114299) in a patient population essentially identical to that of EGF30008 except that subjects must have received prior treatment with trastuzumab, with aromatase inhibitor (AI) + trastuzumab included as the reference arm.
Randomiziranega in kontroliranega kliničnega preskušanja (EGF114299) pri populaciji bolnikov, v bistvu identični populaciji v EGF30008, le da so morali preiskovanci predhodno prejemati zdravljenje s trastuzumabom, zaviralcem aromataze (AI - aromatase inhibitor) + trastuzumabom, vključenim v referenčni krak.
A randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients.
V okviru randomizirane, multicentrične, kontrolirane študije z virusom HIV okuženih pediatričnih bolnikov, je bila opravljena randomizirana primerjava režima odmerjanja abakavirja in lamivudina enkrat v primerjavi z dvakrat na dan.
A randomised double-blind morbidity-mortality study called the Antihypertensive and Lipid- Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACE- inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension.
Randomizirano, dvojno slepo študijo obolevnosti in umrljivosti z nazivom Študija antihipertenzivnega zdravljenja in zniževanja vrednosti lipidov za preprečevanje srčnega infarkta (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial - ALLHAT) so izvajali zato, da bi ocenili novejše načine zdravljenja: amlodipin 2,5-10 mg/dan (zaviralec kalcijevih kanalčkov) ali lizinopril 10-40 mg/dan (zaviralec ACE) kot zdravili prvega izbora v primerjavi s tiazidnim diuretikom klortalidonom 12,5-25 mg/dan pri blagi do zmerni hipertenziji.
A randomised double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension.
Randomizirano, dvojno slepo študijo obolevnosti in umrljivosti z nazivom Študija antihipertenzivnega zdravljenja in zniževanja vrednosti lipidov za preprečevanje srčnega infarkta (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial - ALLHAT) so izvajali zato, da bi ocenili novejše načine zdravljenja: amlodipin 2,5-10 mg/dan (zaviralec kalcijevih kanalčkov) ali lizinopril 10- 40 mg/dan (zaviralec ACE) kot zdravili prvega izbora v primerjavi s tiazidnim diuretikom klortalidonom 12,5-25 mg/dan pri blagi do zmerni hipertenziji.
A randomised Phase III study (EGF111438) (N=540) compared the effect of the two regimens on the incidence of CNS as site of first relapse in women with HER2 overexpressing metastatic breast cancer.
Randomizirana študija III. faze (EGF111438) (n = 540) je primerjala učinek obeh shem na incidenco osrednjega živčevja kot mesta prvega relapsa pri ženskah z metastatskim rakom dojke s čezmerno ekspresijo HER2.
A randomised study assessed the clinical efficacy response rate in DMARD-naïve patients (n = 121) with early RA, who received either 20 mg or 100 mg of leflunomide with matching placebo in two parallel groups during the init ial threeday double blind period.
Randomizirana študija je ocenila delež odzivnosti pri bolnikih (n = 121), ki še niso bili zdravljeni z imunomodulirajočimi protirevmatičnimi zdravili, so imeli zgoden RA in so med uvodnim tridnevnim dvojno slepim obdobjem prejemali bodisi 20 mg bodisi 100 mg leflunomida v dveh vzporednih skupinah.
A randomised, double blind, placebo-controlled phase II study (RISE-IIP) to evaluate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) was terminated early.
Randomizirana, dvojno slepa, s placebom nadzorovana študija II. faze (RISE-IIP), ki je vrednotila učinkovitost in varnost riociguata pri bolnikih s simptomatsko pljučno hipertenzijo, povezano z idiopatsko intersticijsko pljučnico (PH-IIP), je bila predčasno zaključena.
A randomised, double-blind, multi-national, placebo controlled, phase III study (PATENT-1) was conducted in 443 adult patients with PAH (riociguat individual dose titration up to 2.5 mg three times daily: n=254, placebo: n=126, riociguat “capped” dose titration (CT) up to 1.5 mg (exploratory dose arm, no statistical testing performed; n=63)).
V randomizirano, dvojno slepo, multinacionalno, s placebom nadzorovano študijo faze III (PATENT-1) je bilo vključenih 443 odraslih bolnikov s PAH (titriranje odmerka riociguata za posameznega bolnika do 2,5 mg trikrat na dan: n = 254, placebo: n = 126, navzgor omejeno titriranje odmerka riociguata (CT – ''capped'' dose titration) do 1,5 mg (skupina za določanje odmerka, statistična analiza ni bila izvedena; n = 63)).
A randomised, double-blind, parallel-group non-inferiority study compared the relative efficacy of two different daily maintenance doses of leflunomide, 10 mg and 20 mg.
V randomizirani, dvojno slepi študiji na dveh paralelnih enakovrednih skupinah so primerjali relativno učinkovitost dveh različnih dnevnih vzdrževalnih odmerkov leflunomida, 10 mg in 20 mg.
A randomised, double-blind, placebo-controlled study was conducted in 405 patients with pulmonary arterial hypertension.
Randomizirana, dvojno slepa, s placebom kontrolirana študija je bila opravljena na 405 bolnikih s pljučno arterijsko hipertenzijo.
A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azole- susceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline).
Randomizirana, s "slepim ocenjevalcem" kontrolirana študija je bila opravljena pri bolnikih, okuženih z virusom HIV, ki so imeli na azole občutljivo orofaringealno kandidozo (pri večini bolnikov v tej študiji so na začetku študije izolirali C. albicans).
A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azole- susceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline).
Randomizirana, za ocenjevalce slepa kontrolirana študija je bila opravljena pri bolnikih, okuženih s HIV, ki so imeli na azole občutljivo orofaringealno kandidiazo (pri večini bolnikov v tej študiji so na začetku študije izolirali C. albicans).
A randomised, open-label cross-over study was performed in children and adolescents with asthma (aged 4- 17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD) (aged older than 55 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Pri otrocih in mladostnikih z astmo (starih od 4 do 17 let), odraslih z astmo (starih od 18 do 45 let), odraslih s kronično obstruktivno pljučno boleznijo (KOPB) (starejših od 55 let) in zdravih prostovoljcih (starih od 18 do 45 let) so opravili randomizirano, odprto križno študijo za ocenitev največje inspiratorne hitrosti pretoka (PIFR, peak inspiratory flow rate) in drugih povezanih inhalacijskih parametrov po inhaliranju iz pripomočka Spiromax (s placebom) v primerjavi z inhaliranjem iz večodmernega pripomočka za inhaliranje s suhim praškom (s placebom), ki je na trgu.
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD – aged >50 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Izvedli so randomizirano odprto študijo s placebom, v katero so vključili otroke in mladostnike z astmo (stare 6-17 let), odrasle z astmo (stare 18-45 let), odrasle s kronično obstruktivno pljučno boleznijo (KOPB) (stare > 50 let) ter zdrave prostovoljce (stare 18-45 let), da bi ocenili najvišje stopnje vdišnega toka (PIFR- peak inspiratory flow rate) in druge povezane vdišne parametre po inhalaciji iz inhalatorjem Spiromax (ki vsebuje placebo) v primerjavi z inhalacijo iz drugega večodmernega inhalatorja s suhim praškom (ki je vseboval placebo) na trgu.
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD – aged >50 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device(containing placebo).
Izvedli so randomizirano odprto študijo s placebom, v katero so vključili otroke in mladostnike z astmo (stare 6–17 let), odrasle z astmo (stare 18–45 let), odrasle s kronično obstruktivno pljučno boleznijo (KOPB) (stare > 50 let) ter zdrave prostovoljce (stare 18–45 let), da bi ocenili najvišjo stopnje vdišnega toka (PIFR- peak inspiratory flow rate) in druge povezane vdišne parametre po inhalaciji iz inhalatorja Spiromax (ki je vseboval placebo) v primerjavi z inhalacijo iz drugega večodmernega inhalatorja s suhim praškom na trgu (ki je vseboval placebo).
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Izvedli so randomizirano odprto študijo s placebom, v katero so vključili otroke in mladostnike z astmo (stare 6–17 let), odrasle z astmo (stare 18–45 let) ter zdrave prostovoljce (stare 18–45 let), da bi ocenili najvišjo stopnje vdišnega toka (PIFR- peak inspiratory flow rate) in druge povezane vdišne parametre po inhalaciji iz inhalatorja Spiromax (ki je vseboval placebo) v primerjavi z inhalacijo iz drugega večodmernega inhalatorja s suhim praškom na trgu (ki je vseboval placebo).
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years)and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Izvedli so randomizirano odprto študijo s placebom, v katero so vključili otroke in mladostnike z astmo (stare 6-17 let), odrasle z astmo (stare 18-45 let) ter zdrave prostovoljce (stare 18-45 let), da bi ocenili najvišje stopnje vdišnega toka (PIFR- peak inspiratory flow rate) in druge povezane vdišne parametre po inhalaciji iz inhalatorjem Spiromax (ki vsebuje placebo) v primerjavi z inhalacijo iz drugega večodmernega inhalatorja s suhim praškom (ki je vseboval placebo) na trgu.
A randomised, open-label study was conducted to evaluate the efficacy and safety of Empliciti in combination with lenalidomide and dexamethasone in patients with multiple myeloma who have received one to three prior therapies.
Odprta randomizirana študija, izvedena za ovrednotenje učinkovitosti in varnosti zdravila Empliciti v kombinaciji z lenalidomidom in deksametazonom pri bolnikih z multiplim mielomom, ki so se predhodno zdravili z eno do tremi oblikami zdravljenja.
A randomised, open-label, multicentre study of 1,053 patients evaluated the efficacy of bevacizumab and oxaliplatin- or irinotecan-containing chemotherapeutic regimens with and without Vectibix in the first-line treatment of metastatic colorectal cancer.
Randomizirana, odprta, multicentrična študija 1.053 bolnikov je raziskala učinkovitost bevacizumaba ter shem kemoterapije, ki vključujejo oksaliplatin ali irinotekan, z zdravilom Vectibix in brez njega kot terapije prve izbire pri metastatskem kolorektalnem raku.
A randomised, placebo-controlled, double-blind study was conducted post-approval to evaluate the efficacy of palifermin given pre- or pre- and post- chemotherapy (CT).
Randomizirana, s placebom kontrolirana, dvojno slepa študija za oceno učinkovitosti palifermina, uporabljenega pred ali pred in po kemoterapiji (KT) je bila opravljena po odobritvi zdravila.
A randomized and double-blinded study evaluated abatacept SC in combination with methotrexate (abatacept + MTX), abatacept SC monotherapy, or methotrexate monotherapy (MTX group) in induction of remission following 12 months of treatment, and maintenance of drug-free remission after complete drug withdrawal in MTX-naive adult patients with highly active early rheumatoid arthritis with poor prognostic factors.
V randomizirani, dvojno slepi študiji so vrednotili subkutano (s.c.) uporabo abatacepta v kombinaciji z metotreksatom (abatacept + MTX), subkutano uporabo abatacepta v monoterapiji ali uporabo metotreksata v monoterapiji (skupina z MTX) pri indukciji remisije po 12-mesečnem zdravljenju in ohranitev remisije v času brez uporabe zdravila po popolni odtegnitvi zdravila pri odraslih bolnikih z močno aktivnim zgodnjim revmatoidnim artritisom s slabimi prognostičnimi dejavniki, ki se predhodno še niso zdravili z MTX.
A randomized, double-blind study was conducted to assess the safety and efficacy of abatacept or infliximab versus placebo in patients with an inadequate response to methotrexate (Study V).
Pri bolnikih z nezadostnim odzivom na metotreksat je bila izvedena randomizirana, dvojno slepa študija, ki je vrednotila varnost in učinkovitost abatacepta ali infliksimaba v primerjavi s placebom (Študija V).
A randomized, double-blind study was conducted to assess the safety and efficacy of intravenous abatacept or infliximab versus placebo in patients with an inadequate response to methotrexate (Study V).
Pri bolnikih z nezadostnim odzivom na metotreksat je bila izvedena randomizirana, dvojno slepa študija, ki je vrednotila varnost in učinkovitost intravenske uporabe abatacepta ali infliksimaba v primerjavi s placebom (Študija V).
A randomized, double-blind, placebo--controlled study (Study 58) was conducted to demonstrate safety and efficacy of vandetanib 300 mg versus placebo.
Opravljena je bila randomizirana, dvojno slepa, s placebom kontrolirana študija (študija 58) varnosti in učinkovitosti 300 mg vandetaniba v primerjavi s placebom.
A randomized, double-blind, placebo-controlled study (Study 58) was conducted to demonstrate safety and efficacy of vandetanib 300 mg versus placebo.
Opravljena je bila randomizirana, dvojno slepa, s placebom kontrolirana študija (študija 58) varnosti in učinkovitosti 300 mg vandetaniba v primerjavi s placebom.
A randomized, single(investigator)-blinded, non-inferiority study was conducted to assess the safety and efficacy of weekly subcutaneous (SC) abatacept without an abatacept intravenous (IV) loading dose versus every-other-weekly subcutaneous adalimumab, both with background MTX, in patients with an inadequate response to methotrexate (Study SC-II).
Pri bolnikih z nezadostnim odzivom na metotreksat je bila izvedena randomizirana, enojno slepa (raziskovalec) študija, ki je vrednotila neinferiornost varnosti in učinkovitosti tedenske subkutane (s.c.) uporabe abatacepta brez intravenskega (i.v.) polnilnega odmerka v primerjavi s subkutano uporabo adalimumaba vsak drugi teden, oboje skupaj z osnovnim zdravljenjem z metotreksatom (MTX) (študija SC-II).
A range of different chest symptoms were reported as treatment-related adverse reactions and were referred to as non-specific chest pain..
O različnih torakalnih simptomih so poročali kot o neželenih učinkih, povezanih z zdravilom, in jih imenovali nespecifična bolečina v prsih.
A rapid and sustained decrease in the levels of the inflammatory biomarkers; serum amyloid A (SAA), C- reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and a normalization of inflammatory hematological changes are seen.
Opaziti je hitro in trajajoče zmanjšanje ravni bioloških označevalcev vnetja, serumskega amiloida A (SAA), C-reaktivnega proteina (CRP) in sedimentacije eritrocitov (ESR) ter normalizacijo hematoloških sprememb vnetja.
A rapid decrease in CRP levels was also observed in patients with Crohn’s disease.
Pri pacientih s Crohnovo boleznijo so opazili tudi naglo znižanje koncentracij CRP.
A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira.
Pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom, Crohnovo boleznijo, ulceroznim kolitisom in hidradenitis suppurativa so opazili naglo znižanje koncentracij CRP po zdravljenju z zdravilom Humira.
A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira.
Pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom, Crohnovo boleznijo, ulceroznim kolitisom in hidradenitis suppurativa so opazili tudi naglo znižanje koncentracij CRP po zdravljenju z zdravilom Humira.
A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira.
Pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom, Crohnovo boleznijo, ulceroznem kolitisom in hidradenitis suppurativa so opazili tudi naglo znižanje koncentracij CRP po zdravljenju z zdravilom Humira.
A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira.
Pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom, Crohnovo boleznijo, ulceroznem kolitisom in hidradenitis suppurativaso opazili tudi naglo znižanje koncentracij CRP po zdravljenju z zdravilom Humira.